Fannin Innovation Studio Forms Molecular Therapeutics Company Exotect, LLC.
Summary
More than 25 million people suffer with asthma, a chronic disease in which airways become inflamed, swell and produce excess mucus making it difficult to breathe.Fannin Innovation Studio principal Dev Chatterjee, M.D., Ph.D., and entrepreneurship fellow Melissa Singh, Ph.D., will lead Exotect’s research and development activities.Houston, TX, November 07, 2015 --( PR.com )-- Fannin Innovation Studio, a commercialization firm that provides integrated funding and direct management of early-stage life science startups, today announced the formation of Exotect, LLC.Our goal is to offer an additional effective treatment in asthma and other airway diseases by treating mucus hypersecretion,” said Dickey.Exotect will continue further scientific discoveries, primarily under the stewardship of Dickey and his team, in conjunction with drug discovery focused on the molecular target, by multiple approaches including high throughput screening and rational drug design.Fannin Innovation Studio principal Dev Chatterjee, M.D., Ph.D., and entrepreneurship fellow Melissa Singh, Ph.D., will lead Exotect’s research and development activities.“Fannin’s core strategy is to develop paradigm-changing research that has optionality for more than one indication,” said Fannin managing partner Atul Varadhachary, M.D., Ph.D. “Currently, there are no therapeutic interventions which treat this important component of asthma, which is the hypersecretion of mucus.”The formation of Exotect is part of Fannin’s growth strategy to co-found ten to fifteen more early-stage life science companies within the next three years.